ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

This study has been terminated.
(side effect profile did not match expectations)
Sponsor:
Information provided by:
elbion AG
ClinicalTrials.gov Identifier:
NCT00439192
First received: February 22, 2007
Last updated: August 7, 2007
Last verified: August 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2007
  Estimated Primary Completion Date: No date given